{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:01:59Z","timestamp":1784674919779,"version":"3.55.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2018-12365530"],"award-info":[{"award-number":["RF-2018-12365530"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec013\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>The study aims to analyze care and cost patterns in the Veneto region for cancer patients in the final phase of their disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec014\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The study cohort includes adult patients alive on 1.1.2018, which have been diagnosed with cancer at the age 15+ in a 28-years period, spanning from 1990 to 2017, and died within 12 months from prevalence date. The end-of-life (EOL) prevalent cases included in the study cohort are identified by the Veneto Tumor Registry. Primary tumors considered in the analysis are colon, rectum, skin melanoma, female breast, thyroid. Patient monthly average EOL costs, patient annual average EOL costs and total regional costs have been estimated separately for each cancer site\/sex\/age group\/health care service database.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec015\">\n<jats:title>Results<\/jats:title>\n<jats:p>The estimated EOL total cost, for the five analyzed cancer types in the Veneto Region, is approximately 53 million euros. Costs associated with cancer treatment tend to increase in the final phase of the disease. In general, Hospital Admission is the main driver cost in all types of cancer considered, with the only exception in melanoma, where Hospital Drugs features the highest contribution. Moreover, costs differ significantly depending on the type of cancer, gender, and age, revealing highest average costs associated with younger patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec016\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study provides a comprehensive analysis of healthcare budget distribution in the last year of life, enabling healthcare planners to predict cancer burden in the future. This model can be applied to other Italian regions and countries with different healthcare systems.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0318849","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T18:30:43Z","timestamp":1739557843000},"page":"e0318849","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost profiles of cancer patients at the end of life: Estimates from the EPICOST-study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4908-5506","authenticated-orcid":true,"given":"Stefano","family":"Guzzinati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6528-5713","authenticated-orcid":true,"given":"Alessandra","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-0608","authenticated-orcid":true,"given":"Silvia","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gagliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pierannunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Buja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Zorzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"pone.0318849.ref001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.01.011","article-title":"The cost of cancer in Europe 2018","volume":"129","author":"T Hofmarcher","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0318849.ref002","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12885-018-4053-y","article-title":"Characteristics of people living in Italy after a cancer diagnosis in 2010 and projections to 2020","volume":"18","author":"S Guzzinati","year":"2018","journal-title":"BMC Cancer"},{"key":"pone.0318849.ref003","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.2147\/CMAR.S380390","article-title":"Cancer cure and consequences on survivorship care: position paper from the Italian alliance against cancer (ACC) survivorship care working group","volume":"14","author":"L Dal Maso","year":"2022","journal-title":"Cancer Manag Res"},{"issue":"7","key":"pone.0318849.ref004","doi-asserted-by":"crossref","first-page":"103635","DOI":"10.1016\/j.esmoop.2024.103635","article-title":"Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030","volume":"9","author":"S Guzzinati","year":"2024","journal-title":"ESMO Open"},{"issue":"7","key":"pone.0318849.ref005","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1377\/hlthaff.2017.0167","article-title":"Disparities in cancer care and costs at the end of life: evidence from England\u2019s National Health Service","volume":"36","author":"B Walsh","year":"2017","journal-title":"Health Aff (Millwood)"},{"issue":"7","key":"pone.0318849.ref006","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10198-020-01190-z","article-title":"Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data","volume":"21","author":"S Francisci","year":"2020","journal-title":"Eur J Health Econ"},{"issue":"2","key":"pone.0318849.ref007","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/ijerph18020474","article-title":"The economic impact of rectal cancer: a population-based study in Italy","volume":"18","author":"A Gigli","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"pone.0318849.ref008","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/MLR.0000000000000330","article-title":"Patterns of cancer care costs in a country with detailed individual data","volume":"53","author":"T Blakely","year":"2015","journal-title":"Med Care"},{"issue":"1","key":"pone.0318849.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12904-017-0213-0","article-title":"Health care use and costs at the end of life: a comparison of elderly Australian decedents with and without a cancer history","volume":"17","author":"R Reeve","year":"2017","journal-title":"BMC Palliat Care"},{"issue":"7","key":"pone.0318849.ref010","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","article-title":"Medical care costs associated with cancer survivorship in the United States","volume":"29","author":"AB Mariotto","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"pone.0318849.ref011","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0300891620961839","article-title":"Cancer prevalence by phase of care: an indicator for assessing health service needs","volume":"107","author":"A Gigli","year":"2021","journal-title":"Tumori"},{"key":"pone.0318849.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.socscimed.2017.04.038","article-title":"Counting the time lived, the time left or illness? Age, proximity to death, morbidity and prescribing expenditures","volume":"184","author":"PV Moore","year":"2017","journal-title":"Soc Sci Med"},{"issue":"7","key":"pone.0318849.ref013","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10198-021-01304-1","article-title":"Evolution of health care utilization and expenditure during the year before death in 2015 among people with cancer: French snds-based cohort study","volume":"22","author":"A Tanguy-Melac","year":"2021","journal-title":"Eur J Health Econ"},{"issue":"6","key":"pone.0318849.ref014","doi-asserted-by":"crossref","first-page":"75s","DOI":"10.1200\/JOP.2011.000469","article-title":"Health care costs for patients with cancer at the end of life","volume":"8","author":"B Chastek","year":"2012","journal-title":"J Oncol Pract"},{"key":"pone.0318849.ref015","volume-title":"Organization and financing of public health services in Europe: country reports [Internet]","author":"B Rechel","year":"2018"},{"key":"pone.0318849.ref016","doi-asserted-by":"crossref","first-page":"974505","DOI":"10.3389\/fpubh.2022.974505","article-title":"Cancer cost profiles: the Epicost estimation approach","volume":"10","author":"S Francisci","year":"2022","journal-title":"Front Public Health"},{"issue":"9","key":"pone.0318849.ref017","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s10198-021-01327-8","article-title":"A direct method for the identification of patterns of care using administrative databases: the case of breast cancer","volume":"22","author":"S Busco","year":"2021","journal-title":"Eur J Health Econ"},{"key":"pone.0318849.ref018","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2022"},{"issue":"10","key":"pone.0318849.ref019","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/0269216314533813","article-title":"Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: a systematic review","volume":"28","author":"JM Langton","year":"2014","journal-title":"Palliat Med"},{"issue":"11","key":"pone.0318849.ref020","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/bjc.2016.77","article-title":"Cost of care for cancer patients in England: evidence from population-based patient-level data","volume":"114","author":"M Laudicella","year":"2016","journal-title":"Br J Cancer"},{"issue":"1","key":"pone.0318849.ref021","first-page":"25","article-title":"Hospital, local palliative care network and public health: how do they involve terminally ill patients?","volume":"27","author":"G Scaccabarozzi","year":"2017","journal-title":"Eur J Public Health"},{"issue":"8","key":"pone.0318849.ref022","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.healthpol.2021.06.005","article-title":"How have casemix, cost and hospital stay of inpatients in the last year of life changed over the past decade? Evidence from Italy","volume":"125","author":"P Berta","year":"2021","journal-title":"Health Policy"},{"issue":"9","key":"pone.0318849.ref023","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/djn103","article-title":"Cost of care for elderly cancer patients in the United States","volume":"100","author":"KR Yabroff","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"pone.0318849.ref024","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"LE Schnipper","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0318849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T18:31:01Z","timestamp":1739557861000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0318849"}},"subtitle":[],"editor":[{"given":"Monia","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0318849","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}